OICR
Nurosene Health, Ontario Institute for Cancer Research Team for Pancreatic Cancer Research
Nurosene's NetraMark subsidiary will use its AI platform to analyze genome sequencing data from pancreatic cancer patients in order to help personalize treatments.
Large-Scale Pan-Cancer Analysis Expands Set of Alterations Disrupting Key Genes, Pathways
Members of a large, international consortium tapped into whole-genome sequences from nearly 2,700 tumors to explore coding and non-coding variants contributing to cancer.